Cargando…
Omalizumab for Chinese patients with moderate-to-severe allergic asthma in real-world clinical setting: a prospective, observational study
BACKGROUND: We aimed to investigate the effectiveness of omalizumab, a monoclonal anti-immunoglobulin E antibody, in Chinese patients with moderate-to-severe allergic asthma in real-world clinical practice. METHODS: This single-centre, prospective, observational study included Chinese patients aged...
Autores principales: | Wang, Wen, Li, Jieying, Zou, Congying, Zhao, Lifang, Zhu, Ya, Guo, Yue, Wang, Feiran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514615/ https://www.ncbi.nlm.nih.gov/pubmed/37734750 http://dx.doi.org/10.1136/bmjresp-2022-001549 |
Ejemplares similares
-
Asthma exacerbation prevalence during the COVID-19 lockdown in a moderate-severe asthma cohort
por: de Boer, Geertje, et al.
Publicado: (2021) -
Economic analysis of temperature-controlled laminar airflow (TLA) for the treatment of patients with severe persistent allergic asthma
por: Brazier, Peter, et al.
Publicado: (2016) -
Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma
por: Chan, Rory, et al.
Publicado: (2023) -
Managing moderate-to-severe paediatric asthma: a scoping review of the efficacy and safety of fluticasone propionate/salmeterol
por: Pitrez, Paulo Marcio, et al.
Publicado: (2023) -
Concordance of opinions between patients and physicians and their relationship with symptomatic control and future risk in patients with moderate–severe asthma
por: Crespo-Lessmann, Astrid, et al.
Publicado: (2017)